Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 10, Number 2, February 2018, pages 117-124

Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril

Figures

Figure 1.
Figure 1. Changes of blood pressure and heart rate during the study period. Systolic and diastolic blood pressure decreased significantly in both groups. The heart rate remained at approximately the same level.
Figure 2.
Figure 2. Changes of eGFR. There was no significant difference in the mean eGFR and the change of eGFR. NS: not significant.
Figure 3.
Figure 3. Changes of eGFR in diabetic patients. The mean eGFR decreased significantly in the amlodipine group, but not in the benidipine group. However, there was no significant difference in the change of eGFR. NS: not significant.
Figure 4.
Figure 4. Changes of urinary albumin excretion. There was no significant difference in the mean urinary albumin excretion and the change of urinary albumin excretion. NS: not significant.
Figure 5.
Figure 5. Changes of urinary albumin excretion in diabetic patients. There was no significant difference in the mean urinary albumin excretion and the change of urinary albumin excretion in diabetic patients. NS: not significant.
Figure 6.
Figure 6. Changes of qualitative urine protein excretion. P < 0.05 vs. baseline. Qualitative urine protein excretion was significantly improved in both groups.

Table

Table 1. Patient Characteristics
 
Amlopidine group (n = 62)Benidipine group (n = 59)P-value
BMI: body mass index; Cr: creatinine; eGFR: estimated glomerular filtration rate.
Gender (male/female)38/2437/21NS
Age (years)68.9 ± 10.269.0 ± 9.1NS
BMI (kg/m2)25.4 ± 3.725.2 ± 3.5NS
Smoking (yes/past/no)15/19/2813/15/31NS
Drinking (yes/no)43/3746/30NS
Perindopril (mg/day)4.2 ± 1.24.2 ± 0.9NS
Complications (n (%))57 (91)54 (91)NS
Diabetes mellitus (n (%))24 (39)28 (47)NS
Dyslipidemia (n (%))33 (53)31 (52)NS
Hyperuricemia (n (%))16 (25)12 (21)NS
Coronary artery disease (n (%))10 (16)11 (19)NS
Heart failure (n (%))9 (10)14 (16)NS
Cerebrovascular disease (n (%))5 (8)4 (7)NS
Renal failure (n (%))2 (3)0(0)NS